Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion/MECOM rearrangement
The prognosis of MECOMr AML is poor, with a 5-year overall survival (OS) rate of less than 10%. This is mostly attributable to the low efficacy of all available therapies and high relapse rates even after allogeneic stem cell transplantation (alloSCT), which remains the only curative approach. We re...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-03-01
|
| סדרה: | Frontiers in Oncology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530852/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|